Adiponectin levels in plasma showed a significant increase by pioglitazone treatment in both time points when comparing CKD and CKD + Pio groups, indicative for successful PPARγ target gene activation (Maeda et al., 2001; Iwaki et al., 2003). Here, PPARG is linked to chronic kidney disease.